BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23218687)

  • 1. Erythropoietin in cancer: a dilemma in risk therapy.
    Cao Y
    Trends Endocrinol Metab; 2013 Apr; 24(4):190-9. PubMed ID: 23218687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression.
    Hedley BD; Allan AL; Xenocostas A
    Clin Cancer Res; 2011 Oct; 17(20):6373-80. PubMed ID: 21750199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin use in CKD patients with cancer: to tread with caution?
    Nayak-Rao S; McCormick B
    J Nephrol; 2013; 26(5):829-35. PubMed ID: 24052463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EPO in cancer anemia: benefits and potential risks.
    Milano M; Schneider M
    Crit Rev Oncol Hematol; 2007 May; 62(2):119-25. PubMed ID: 17197190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human erythropoietin in combination with chemotherapy increases breast cancer metastasis in preclinical mouse models.
    Hedley BD; Chu JE; Ormond DG; Beausoleil MS; Boasie A; Allan AL; Xenocostas A
    Clin Cancer Res; 2011 Oct; 17(19):6151-62. PubMed ID: 21856770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative administration of erythropoietin stimulates tumor recurrence after surgical excision of colon cancer in mice by a vascular endothelial growth factor-independent mechanism.
    Pascual M; Bohle B; Alonso S; Mayol X; Salvans S; Grande L; Pera M
    J Surg Res; 2013 Jul; 183(1):270-7. PubMed ID: 23348072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Research advances in expression and functions of erythropoietin and erythropoietin receptor in cancers].
    Li M; Lu Y; Chen XQ
    Ai Zheng; 2008 Jun; 27(6):667-72. PubMed ID: 18570746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin: the swinging pendulum.
    Oster HS; Neumann D; Hoffman M; Mittelman M
    Leuk Res; 2012 Aug; 36(8):939-44. PubMed ID: 22579365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin biology in cancer.
    Hardee ME; Arcasoy MO; Blackwell KL; Kirkpatrick JP; Dewhirst MW
    Clin Cancer Res; 2006 Jan; 12(2):332-9. PubMed ID: 16428469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human erythropoietin β: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients.
    Durmaz O; Demirkaya M; Sevinir B
    Pediatr Hematol Oncol; 2011 Sep; 28(6):461-8. PubMed ID: 21707225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin in cancer patients.
    Glaspy JA
    Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies.
    Henry DH; Abels RI
    Semin Oncol; 1994 Apr; 21(2 Suppl 3):21-8. PubMed ID: 8202722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxygen breathing may be a cheaper and safer alternative to exogenous erythropoietin (EPO).
    Burk R
    Med Hypotheses; 2007; 69(6):1200-4. PubMed ID: 17493766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The blue cross blue shield assessment technology review: summary of findings.
    Bennett CL
    Best Pract Res Clin Haematol; 2005; 18(3):423-31. PubMed ID: 15792916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
    Lissoni P; Rovelli F; Baiocco N; Tangini G; Fumagalli L
    Anticancer Res; 2001; 21(1B):777-9. PubMed ID: 11299843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. To give or not to give recombinant EPO to anemia endangered cancer patients.
    Sulkowska M; Wincewicz A; Chabowska A; Kanczuga-Koda L; Szymanska M; Koda M; Witkowska E; Sulkowski S
    Prague Med Rep; 2006; 107(3):281-9. PubMed ID: 17385400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin for oncology supportive care.
    McKinney M; Arcasoy MO
    Exp Cell Res; 2011 May; 317(9):1246-54. PubMed ID: 21396935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does erythropoietin have a dark side? Epo signaling and cancer cells.
    Sytkowski AJ
    Sci STKE; 2007 Jul; 2007(395):pe38. PubMed ID: 17636183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia.
    Osterborg A; Aapro M; Cornes P; Haselbeck A; Hayward CR; Jelkmann W
    Eur J Cancer; 2007 Feb; 43(3):510-9. PubMed ID: 17150352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Erythropoietin--physiology and therapeutic potentialities].
    Möllmann M
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1992 Dec; 27(8):461-8. PubMed ID: 1489869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.